logo-loader
viewCallitas Health Inc

Callitas Health strikes up partnership with Simply Wholeistic on CannaStrip technology, dietary supplements

Callitas has developed a novel delivery technology that helps achieve more precise dosing — a tricky undertaking when it comes to medical cannabis

THC and CBD
Callitas is a diversified health and wellness company with a portfolio of remedies for sexual health and weight management, as well as orphan drugs and cannabis delivery technologies

Callitas Health Inc (CSE:LILY) (OTCQB:MPHMF) said Monday that it signed a letter of intent with wellness company Simply Wholeistic to manufacture and supply formulations of its own CannaStrips and Simply Wholistic dietary supplements for sale in the US market.

Cincinnati-based health and wellness company Callitas has developed a novel delivery technology that helps achieve more precise dosing — a tricky undertaking when it comes to medical cannabis.

The company has come up with oral strips that dissolve instantly on the tongue to deliver tetrahydrocannabinol (THC) and cannabidiols (CBD), a medical component of cannabis that doesn’t get users high.

READ: Callitas Health strikes up new partnership with NuEthix

The valuable CannaStrip technology has patent-pending status from the US Patent Office.

The new partnership comes on the heels of Callitas Health signing agreements with two undisclosed California companies to market and sell CannStrips for THC and CBD.

“The range of Callitas’s products and IP is outstanding, and the patented sublingual Cannabidiol (CBD) strip is a game changer,″ said Simply Wholeistic CEO Clayton Thomas in a statement. “This year Simply Wholeistic will launch and supply a suite of specific health products that we believe can improve the health of our customers. Our partnership with Callitas significantly enhances our ability to innovate in the market.″

Simply Wholeistic has created a new line of natural alternative and detox supplements that are designed to help consumers practice preventive care and healthy living.

DEEP DIVE: Callitas Health banks on CannaStrips and OTC products while swinging for the fence with blockbuster drugs

″Simply Wholeistic’s distribution model enables Callitas to continue expanding its technologies, including Cannastrip, into nationwide markets,″ said Callitas Health CEO James M Thompson. “We are excited with this new partnership, and we look forward to introducing novel dietary supplements that address a variety of needs.″

Simply Wholeistic develops and distributes a line of products, including a unique mood-balancing Hemp strip, that will provide natural alternatives to synthetic supplements.

Callitas is a well-diversified health and wellness company with a large portfolio. It is developing remedies across five silos: OTC sexual health & wellness, prescriptions for female sexual health, weight management, cannabis delivery technologies and orphan drugs.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Callitas Health Inc

Price: 0.11 CAD

CSE:LILY
Market: CSE
Market Cap: $3.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc named herein, including the promotion by the Company of Callitas Health Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Callitas Therapeutics signs LOI with Simply Wholeistic, updates on THC & CBD...

Callitas Therapeutics (CSE:LILY) (OTCQB:MPHMF) Vice President of Sales & Business Development Joshua Maurice tells Proactive Investors the pharma company has signed a letter of intent with Simply Wholeistic to manufacture  its CannaStrip products in the U.S. Maurice added that as...

on 25/4/19

2 min read